Arvinas (NASDAQ:ARVN) CAO Sells $13,473.28 in Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,108 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $13,473.28. Following the completion of the transaction, the chief accounting officer owned 29,692 shares in the company, valued at $361,054.72. The trade was a 3.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Arvinas Stock Down 0.8%

ARVN stock opened at $13.27 on Friday. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $18.93. The business has a 50-day simple moving average of $12.48 and a 200 day simple moving average of $10.60. The company has a market cap of $848.75 million, a PE ratio of -10.37 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The firm had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. During the same quarter in the previous year, the company earned ($0.63) earnings per share. The company’s quarterly revenue was down 84.0% on a year-over-year basis. On average, analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $20, signaling meaningful upside versus current levels. Read More.
• Positive Sentiment: HC Wainwright raised longer‑range earnings projections for FY2028–FY2030 (FY2028 to $3.09, FY2029 to $1.76, FY2030 to $5.60), implying stronger late‑cycle profitability if clinical/program milestones are met. Read More.
• Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Ikarian among buyers), which can support liquidity and indicate some investor confidence in the pipeline. Read More.
• Neutral Sentiment: Street consensus remains mixed (MarketBeat shows a “Hold” consensus with a $13.47 average target), so analyst moves are not uniform — upgrades from some firms may not sway broader sentiment. Read More.
• Neutral Sentiment: Reported short‑interest figures in recent updates appear to be erroneous (showing 0 shares/NaN), so short‑interest/read‑through risk is unclear until corrected data is published. (data report)
• Negative Sentiment: HC Wainwright sharply cut near‑term estimates (Q1–Q4 2026 and FY2026/FY2027 EPS downgraded), lowering expected profitability this year and next — a near‑term negative catalyst for the stock. Read More.
• Negative Sentiment: Q4 2025 results were a clear negative: EPS and revenue missed materially (reported -$1.10 EPS vs. -$0.55 expected; revenue $9.5M vs. $37.3M expected), which is the primary driver pressuring the share price. Read More.
• Negative Sentiment: Insider sales: CEO Randy Teel and CAO David Loomis sold shares on Feb. 23 (modest reductions). Insider selling can be perceived negatively even when routine; filings: Read More., Read More.

Institutional Trading of Arvinas

Hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC grew its holdings in shares of Arvinas by 7.2% during the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock worth $176,000 after purchasing an additional 993 shares during the last quarter. Intech Investment Management LLC boosted its position in Arvinas by 3.6% during the 3rd quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock worth $278,000 after buying an additional 1,125 shares during the period. MetLife Investment Management LLC boosted its position in Arvinas by 4.3% during the 4th quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock worth $401,000 after buying an additional 1,381 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after acquiring an additional 2,122 shares during the last quarter. Finally, Oxford Asset Management LLP increased its position in Arvinas by 15.5% in the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after acquiring an additional 2,242 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ARVN has been the subject of several recent analyst reports. Barclays upped their target price on Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Piper Sandler restated an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a research report on Wednesday. Stephens lifted their target price on Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Finally, Wall Street Zen raised shares of Arvinas from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Ten investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Arvinas currently has an average rating of “Hold” and an average price target of $13.47.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.